Robust real-world data on the effectiveness of biologic therapies in children with severe asthma remain limited, particularly ...

Nonclinical factors are more likely to drive discontinuation of biologic therapy for patients with severe asthma.

Move comes 2 years after controversial exit of brand-name product ...

Asthma biologic use was not associated with an increase in respiratory infection risk, according to results from the 2026 ...

For patients with asthma, receipt of immune checkpoint inhibitor (ICI) therapy for melanoma or renal cell carcinoma is not ...

Among patients with asthma without diabetes, the risk for exacerbation was decreased with GLP-1 receptor agonist exposure, ...

Study results suggest immune checkpoint inhibitor therapy may offer immunomodulatory benefits for patients with asthma and ...

Children with food allergy who used omalizumab plus oral immunotherapy vs. omalizumab alone had similar rates of allergen ...

As an add-on maintenance treatment for severe asthma with type 2 inflammation, characterized by blood eosinophil count in adults and adolescents 12 years and older who are inadequately controlled ...

MILWAUKEE, Feb. 16, 2026 /PRNewswire/ -- Immune checkpoint inhibitors (ICIs) were associated with modest protective effects for patients with asthma, according to new research being presented at the ...

Sometimes the story can be told in statistics. India accounts for 13% of the global population, yet it accounts for 42% of global asthma mortality. Around 35 million Indians are thought to be living ...

This chronic lung condition causes your airways to become permanently widened and scarred. Learn how to spot and treat this ...